Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Appendix
Available only for authorised users
Literature
1.
Williams RT, Yu AL, Diccianni MB, Theodorakis EA, Batova A: Renal cancer-selective Englerin A induces multiple mechanisms of cell death and autophagy. J Exp Clin Cancer Res. 2013, 32: 57-10.1186/1756-9966-32-57.PubMedCentralCrossRefPubMed
Metadata
Title
Erratum to: renal cancer-selective Englerin A induces multiple mechanisms of cell death and autophagy
Authors
Richard T Williams
Alice L Yu
Mitchell B Diccianni
Emmanuel A Theodorakis
Ayse Batova
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2014
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-014-0095-4

Other articles of this Issue 1/2014

Journal of Experimental & Clinical Cancer Research 1/2014 Go to the issue

Research

Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia

Erratum

Erratum to: loss of hsa-miR-337-3p expression is associated with lymph node metastasis of human gastric cancer

Research

SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study

Research

Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion

Research

Transfer of malignant trait to immortalized human cells following exposure to human cancer serum

Research

Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits